Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Feb 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-29

Reporting Person: Hayden Michael R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-29	Common Shares	M	50000	$5.44	Acquired	50000	Direct
2021-01-29	Common Shares	M	30000	$6.06	Acquired	80000	Direct
2021-01-29	Common Shares	M	15000	$6.42	Acquired	95000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-29	Stock Option (right to buy)	$5.44	M	50000	Disposed	2028-02-22	Common Stock (50000.0)	Direct
2021-01-29	Stock Option (right to buy)	$6.06	M	30000	Disposed	2029-01-29	Common Stock (30000.0)	Direct
2021-01-29	Stock Option (right to buy)	$6.42	M	15000	Disposed	2029-07-03	Common Stock (15000.0)	Direct

Footnotes

F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F2: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.